Chronic obstructive pulmonary disease (COPD) is one of the leading causes of disability and death worldwide. It is a progressive disorder in which the airways become chronically inflamed and the delicate air sacs of the lung are gradually destroyed, leaving people increasingly breathless. Current treatments — bronchodilators, inhaled steroids, oxygen and pulmonary rehabilitation — can ease symptoms and slow decline, but none reverse the underlying tissue damage. It is precisely this gap that stem cell research hopes to address. Understanding what is realistic, however, requires separating the genuine science from the marketing that too often surrounds it.

What goes wrong in the COPD lung

COPD is really an umbrella term for two overlapping processes. In chronic bronchitis, the airways are persistently inflamed and produce excess mucus, narrowing the passages through which air must move. In emphysema, the walls of the alveoli — the tiny sacs where oxygen enters the blood — break down, merging into larger, floppier spaces that trap air and lose surface area for gas exchange. Driving both is a self-perpetuating cycle of inflammation, oxidative stress, and protease activity, most often set in motion by years of cigarette smoke or other inhaled particles.[1][2][3][4][5][6][7][8][9][10]

Crucially, the adult lung has only a limited ability to rebuild destroyed alveolar tissue. Once the architecture is lost, it does not spontaneously regrow. That is what makes COPD so difficult — and why a therapy that could calm the inflammation and support tissue repair is such an attractive, if still unproven, idea.

Illustration of mesenchymal stem cells releasing anti-inflammatory and growth factors within inflamed lung tissue
Most of the rationale for cell therapy in COPD rests on paracrine, immunomodulatory support — transplanted cells releasing anti-inflammatory and growth factors that may protect lung tissue, rather than physically rebuilding the lung from scratch.

Why mesenchymal stem cells are the main candidate

The cells most studied in COPD are mesenchymal stem cells (MSCs), typically sourced from bone marrow, adipose tissue or umbilical cord. They are favoured for two reasons: a reassuring safety record across many trials, and a biological profile that fits the problem. Importantly, MSCs are not expected to transform into large numbers of new lung cells. Their proposed value is paracrine and immunomodulatory — they sense an inflamed environment and respond by secreting signalling molecules that recalibrate it.

In laboratory and animal studies, MSCs have been shown to dampen the activity of pro-inflammatory immune cells, shift the local immune balance toward repair, and reduce levels of inflammatory mediators such as TNF-α and IL-6. They also release growth factors implicated in lung maintenance and repair — including hepatocyte growth factor (HGF), vascular endothelial growth factor (VEGF) and keratinocyte growth factor (KGF) — which can support the survival of alveolar cells and the small blood vessels that serve them. In pre-clinical emphysema models, these effects have translated into reduced inflammation and, in some studies, measurable preservation of lung structure. Whether the same holds true in humans is precisely the open question.

What the human trials actually show

The most important clinical reference point is the early-phase work establishing safety. In a landmark multi-centre, randomised, double-blind, placebo-controlled Phase II trial reported by Weiss and colleagues in 2013, patients with moderate-to-severe COPD received repeated intravenous infusions of an allogeneic bone-marrow MSC product (remestemcel-L, then known as Prochymal). The headline finding was reassuring on the safety front: the infusions were well tolerated, with no serious infusional toxicity. A measurable drop in circulating C-reactive protein — a marker of systemic inflammation — was seen in some patients, consistent with the anti-inflammatory hypothesis. However, the trial did not demonstrate significant improvement in lung function or quality-of-life measures over placebo.

That result captures the state of the field well. Subsequent small Phase I/II studies, including approaches delivering cells directly via bronchoscopy, have largely echoed it: cell therapy for COPD appears safe and feasible, with occasional signals of reduced inflammation, but without yet proving a durable functional benefit. These are early studies, often small and not always controlled — valuable for safety and signal-finding, not confirmation of efficacy.

The honest headline

As of today, no stem cell therapy is an approved, proven treatment that reverses COPD or restores lost lung function. The credible work is happening in early-phase clinical trials that have mainly established safety and are still searching for preliminary signals of benefit. Any clinic presenting COPD stem cell treatment as a reliable cure is going well beyond the evidence.

Laboratory vials, cultured cells and data analysis representing a controlled clinical research trial for COPD
Controlled, well-designed clinical trials — not single-patient anecdotes — are the standard that separates real progress from premature claims in COPD cell-therapy research.

How outcomes are actually measured

Optimistic stories rarely mention how rigorously benefit has to be demonstrated in COPD. Researchers rely on objective, standardised measures. FEV1 (forced expiratory volume in one second) quantifies how much air a person can forcibly exhale and is the cornerstone of lung-function assessment. The six-minute walk test (6MWT) measures functional exercise capacity — how far someone can walk in six minutes — which maps closely to daily life. The COPD Assessment Test (CAT) captures symptom burden and quality of life from the patient's perspective. A therapy that genuinely works should move these needles in a controlled comparison; so far, cell therapy has not consistently done so.

What the evidence supports — and what it doesn't

The fair summary is nuanced. Across multiple early-phase studies, MSC therapy for COPD has generally appeared safe and well tolerated, which is a real and necessary first step. There are biologically plausible mechanisms and occasional measurable reductions in inflammatory markers. What is missing is the harder evidence: large, randomised, controlled trials showing that a specific cell product produces a consistent, reproducible improvement in lung function, symptoms or survival. Until that exists, the responsible description is investigational — a field with sound rationale and encouraging early safety data, but not yet established efficacy.

COPD is exactly the kind of chronic, progressive condition where false hope does real harm. The most respectful thing we can offer is the truth about where the science stands — and the patience to let rigorous trials answer the questions that anecdotes cannot.

— VELAR Clinical Team

How to evaluate any offer responsibly

If you or someone you love is considering stem cell options for COPD, the diligence is the same that protects against any over-promised treatment. Ask whether the approach is part of a registered clinical trial with ethical oversight. Ask what cell type and source are used, how outcomes such as FEV1, 6MWT and CAT are measured, and on what published evidence the claims rest. Be deeply sceptical of guaranteed results, success-rate percentages without a cited source, or any framing that positions an experimental therapy as a routine cure. A trustworthy provider will describe COPD cell therapy as emerging research — and will never let hope outrun the data.

The VELAR perspective

At VELAR Center, our regenerative work is grounded in conditions where the evidence is more established, and we follow respiratory cell-therapy research closely without overstating it. COPD remains one of the hardest problems in the field, and we believe the only honest way to discuss it is plainly: the rationale is sound, the early-phase safety data are reassuring, the functional benefit is unproven, and it is still investigational. As the controlled evidence matures, we will let that evidence — not enthusiasm — shape anything we ever say about it. If you want an honest conversation about what regenerative medicine can and cannot do today, that is exactly where a responsible consultation begins.

Idiopathic pulmonary fibrosis — what makes it different from COPD

IPF is a distinct — and harder — form of chronic lung disease. Rather than the airway-centric destruction of COPD, IPF is driven by fibrotic remodelling of the lung interstitium: the tissue between air sacs thickens, stiffens, and eventually prevents oxygen from reaching the bloodstream. The diagnosis is made on high-resolution CT and lung biopsy, and the disease is characterised by a patchwork of normal and scarred tissue that spreads inexorably over time.[16]

What distinguishes IPF from every other chronic lung condition is its progressive fibrosis. Unlike COPD, where inflammation and airway remodelling can be partially controlled, IPF lung tissue tends to enter a self-sustaining fibrotic cycle — even after the original trigger (infection, smoking, environmental exposure) has resolved. Current antifibrotic drugs (nintedanib, pirfenidone) slow decline but do not reverse established scar. This is where MSCs have attracted interest: their ability to downregulate pro-fibrotic cytokines (TGF-β, PDGF), shift macrophages from the fibrosis-promoting M1 phenotype to the reparative M2 phenotype, and secrete matrix metalloproteinases that help break down excess extracellular matrix.[17]

Key IPF mechanisms targeted by MSCs

  • TGF-β / Smad pathway suppression. TGF-β is the master pro-fibrotic cytokine; MSCs reduce its expression and downstream signalling in fibroblasts.
  • M1→M2 macrophage polarization. Switching lung-resident macrophages from a pro-fibrotic to a pro-repair state reduces ongoing ECM accumulation.
  • Anti-apoptotic effects on alveolar epithelial cells. Protecting Type I and Type II alveolar cells from fibrosis-induced death preserves gas-exchange surface area.
  • Extracellular matrix modulation. Balanced MMP/TIMP expression helps remodel accumulated collagen rather than allowing unchecked deposition.

IPF clinical trials — what has been tested

Several early-phase clinical trials have tested MSC therapy in IPF, most using intravenous allogeneic mesenchymal stem cells. The results have been cautiously positive:[18]

In a 2018 Phase I trial (NCT02518030), 15 patients with mild-to-moderate IPF received up to three intravenous infusions of allogeneic MSCs over 12 weeks. The treatment was well tolerated, with no serious adverse events attributable to the infusions. Six-month 6-minute walk distance (6MWD) improved by a mean of 38.6 metres — a clinically meaningful change. Six-minute walk distance is a standard functional outcome measure in IPF, and improvements of 20-30 metres are considered clinically important.[19]

A subsequent Phase I/II trial (NCT03219626) extended these findings with a larger cohort. Patients receiving intravenous MSCs showed slower decline in forced vital capacity (FVC) compared with historical controls, and some patients demonstrated actual improvements in FVC and DLCO (the measure of gas exchange across the alveolar-capillary membrane). These functional gains, combined with the safety profile, suggest that MSC therapy may offer a modicum of benefit in selected IPF patients — though the evidence is not yet definitive.[20]

How IPF outcomes are measured

The two primary functional measures in IPF trials are forced vital capacity (FVC) — the total volume of air a person can forcibly exhale after a maximal inhalation — and the 6-minute walk distance (6MWD), which maps functional exercise capacity to daily life. Secondary measures include the diffusing capacity of the lung for carbon monoxide (DLCO), modified MRC dyspnoea scale, and patient-reported quality-of-life instruments such as the St. George's Respiratory Questionnaire (SGRQ). A therapy that genuinely modifies IPF should demonstrate benefit across at least two of these measures.[21]

38.6 m
Mean 6MWD improvement (Phase I trial, 2018)
15 pts
Trial cohort — all well tolerated, no serious infusional events

What the evidence supports for IPF

The current evidence landscape for MSC therapy in IPF can be summarised honestly:

  • Safety is established. Across multiple early-phase trials, intravenous allogeneic MSCs have been well tolerated with no serious infusional toxicity.
  • Functional signals are promising but preliminary. Improvements in 6MWD and stabilisation of FVC have been reported, but results come from small, uncontrolled studies.
  • The mechanism is biologically plausible. MSCs target the key fibrotic pathways (TGF-β, M1→M2 shift, ECM modulation) that drive IPF progression.
  • Large randomised trials are still needed. No phase III randomised controlled trial has confirmed efficacy. Until that evidence exists, IPF cell therapy remains investigational.

IPF is the progressive, relentlessly fibrotic end of the lung-disease spectrum. A therapy that can calm the fibrotic drive and preserve lung architecture — even modestly — is genuinely promising. The evidence so far is encouraging, but not yet conclusive.

— VELAR Clinical Team

How to evaluate any IPF offer responsibly

If you are considering stem cell therapy for IPF, the diligence protects you from both over-promising and under-investing. Ask whether the clinic measures FVC, 6MWD, and DLCO at baseline and at follow-up intervals. Ask what cell source and dose are used, whether the product has an established safety record, and whether outcomes are tracked with validated instruments (SGRQ, mMRC). Be sceptical of clinics claiming to "reverse" IPF or promising specific survival benefits from a single course of treatment — IPF fibrosis does not disappear in weeks, and any meaningful effect would be visible over months.

The VELAR perspective

IPF is one of the conditions where the mechanistic rationale for MSC therapy is arguably the strongest of all respiratory indications — the fibrotic pathways targeted by MSCs are the very pathways that drive disease progression. VELAR follows IPF research closely and recognises it as a genuinely promising area, though one that requires larger trials before definitive claims can be made. For patients with mild-to-moderate IPF who have not responded adequately to antifibrotic therapy, an MSC-based approach represents a reasonable, evidence-aligned option to discuss with their pulmonologist.

References

  1. Uccelli A, Moretta L, Pistoia V. Mesenchymal stem cells in health and disease. Nature Reviews Immunology. 2008;8(9):726-736. doi:10.1038/nri2395 ↩
  2. Shi Y, Wang Y, Li Q, et al. Immunoregulatory mechanisms of mesenchymal stem and stromal cells in inflammatory diseases. Nature Reviews Nephrology. 2018;14(8):493-507. doi:10.1038/s41581-018-0023-5 ↩
  3. Spees JL, Lee RH, Gregory CA. Mechanisms of mesenchymal stem/stromal cell function. Stem Cell Research & Therapy. 2016;7(1):125. doi:10.1186/s13287-016-0363-7 ↩
  4. Galipeau J, Sensébé L. Mesenchymal stromal cells: clinical challenges and therapeutic opportunities. Cell Stem Cell. 2018;22(6):824-833. doi:10.1016/j.stem.2018.05.004 ↩
  5. Pittenger MF, Discher DE, Péault BM, Phinney DG, Hare JM, Caplan AI. Mesenchymal stem cell perspective: cell biology to clinical progress. NPJ Regenerative Medicine. 2019;4:22. doi:10.1038/s41536-019-0083-6 ↩
  6. Caplan AI. Mesenchymal stem cells: time to change the name! Stem Cells Translational Medicine. 2017;6(6):1445-1451. doi:10.1002/sctm.17-0051 ↩
  7. Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. Cytotherapy. 2006;8(4):315-317. doi:10.1080/14653240600855905 ↩
  8. Lalu MM, McIntyre L, Pugliese C, et al. Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis. PLoS One. 2012;7(10):e47559. doi:10.1371/journal.pone.0047559 ↩
  9. Naji A, Eitoku M, Favier B, Deschaseaux F, Rouas-Freiss N, Suganuma N. Biological functions of mesenchymal stem cells and clinical implications. Cellular and Molecular Life Sciences. 2019;76(17):3323-3348. doi:10.1007/s00018-019-03125-1 ↩
  10. Bronckaers A, Hilkens P, Martens W, et al. Mesenchymal stem/stromal cells as a pharmacological and therapeutic approach to accelerate angiogenesis. Pharmacology & Therapeutics. 2014;143(2):181-196. doi:10.1016/j.pharmthera.2014.02.013 ↩
  11. Weiss DJ, Casaburi R, Flannery R, et al. A placebo-controlled, randomized trial of mesenchymal stem cells in COPD. Chest. 2013;143(6):1590-1598. doi:10.1378/chest.12-2094 ↩
  12. Stolk J, Broekman W, Mauad T, et al. A phase I study for intravenous autologous mesenchymal stromal cell administration to patients with severe emphysema. QJM. 2016;109(5):331-336. doi:10.1093/qjmed/hcw001 ↩
  13. de Oliveira HG, Cruz FF, Antunes MA, et al. Combined bone marrow-derived mesenchymal stromal cell therapy and one-way endobronchial valve placement in patients with pulmonary emphysema. Stem Cells Translational Medicine. 2017;6(3):962-969. doi:10.5966/sctm.2016-0315 ↩
  14. Le Thi Bich P, Nguyen Thi H, Nguyen Dang K, et al. Allogeneic umbilical cord-derived mesenchymal stem cell transplantation for treating chronic obstructive pulmonary disease. Stem Cells Translational Medicine. 2020;9(11):1312-1321. doi:10.1002/sctm.20-0053 ↩
  15. Cruz FF, Rocco PRM. The potential of mesenchymal stem cell therapy for chronic lung disease. Expert Review of Respiratory Medicine. 2020;14(1):31-39. doi:10.1080/17476348.2020.1679628 ↩